跳至主要内容
临床试验/JPRN-UMIN000024234
JPRN-UMIN000024234已完成未知

octuria QOL evaluation in OAB patients treated with Oxybutinin & Mirabegron study - NEOXY study

Department of Urology, school of medicine, Shinshu university0 个研究点目标入组 120 人开始时间: 2016年10月1日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • (1) Patients in the study drug administration proposed site with a skin disease and skin abnormalities. (2) Patients with residual urine volume greater than 100mL. (3) Patients with a difficulty in going to the bathroom without the assistance. (4) Patients with a history of hypersensitivity of Oxybutynin hydrochloride or Mirabegron. (5) Patients receiving flecainide acetate or propafenone hydrochloride. (6) Patients with severe blood, liver, kidney disease and severe arrhythmia, suffering from cardiovascular diseases such as congestive heart failure. (7) Patients with hypokalemia (less than 3.5mEq / L). (8) Patients with paralytic ileus, ulcerative colitis, stomach atony, patients suffering from gastrointestinal diseases, such as bowel atony. (9) Patients with Parkinson's syndrome, dementia, suffering from psychiatric and neurological disorders or cerebrovascular disorders such as myasthenia gravis. (10) Patients with a glaucoma. (11) Patients with a hyperthyroidism. (12) Patients with malignant tumors. (13) Pregnant patients, patients in lactating, and patients want to become pregnant during test period. (14) Patients who participated in the other interventions tested within 16 weeks prior to study drug administration. (15) Other, patient that investigators or test sharing doctor was ineligible as a subject of the present study.

研究者

发起方
Department of Urology, school of medicine, Shinshu university

相似试验